Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$2.7MCash on Hand
9.6mo Cash Runway
Follow BMRA by emailGet an email when BMRA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BMRA, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Oct 16, 2026 ·
Shareholder vote Biomerica will hold its annual meeting on December 11, 2026, where stockholders vote on electing five directors, a non-binding say-on-pay vote, ratifying Haskell & White LLP as auditor, and adding 150,000 shares to the 2024 Stock Incentive Plan. Form DEF 14A · SEC filing
Oct 15, 2026 ·
Leadership A director, David Moatazedi, told the board on October 12, 2026 that he will not stand for re-election at the December 11, 2026 annual meeting. The filing says the decision was not due to any dispute with the company or board. Form 8-K · SEC filing
Oct 15, 2026 ·
Quarterly report for the period ended Aug 31, 2026 Form 10-Q · SEC filing
Sep 28, 2026 ·
Amended annual report for the period ended May 31, 2026 Form 10-K/A · SEC filing
Sep 24, 2026 ·
Financing Biomerica registered up to 1,403,705 shares of common stock for resale by selling stockholders, with the company receiving no proceeds. The last reported price on September 23, 2026 was $2.60 per share. Form S-3 · SEC filing
Sep 24, 2026 ·
Financing Biomerica filed a shelf registration statement for up to $250,000,000 of common stock, preferred stock, debt securities and warrants, with terms and amounts to be set in future offerings. The stock last traded at $2.60 on Sep 23, 2026. Form S-3 · SEC filing
Aug 31, 2026 ·
Annual report for the period ended May 31, 2026 Form 10-K · SEC filing
Aug 26, 2026 ·
Financing Entered a $2.23 million private placement of 1,393,705 common shares at $1.60 per share, with closing on August 26, 2026. B. Riley Principal Capital and certain directors and officers are purchasers. B. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2021 · N/A · Results Expected · Endpoint Determination Study Protocol Registry primary completion date, not a results date
May 2021 · N/A · Results Expected · Specimen Collection Study Protocol Registry primary completion date, not a results date
Mar 2020 · N/A · Results Expected · Specimen Collection Study for H. Pylori Testing Registry primary completion date, not a results date
💰 Cash Runway & Dilution Risk
BMRA holds $2.7M in cash and short-term investments (as of Aug 31, 2026) and burns about $857,000/quarter from operations,
an estimated runway of 9.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:90 · High
Cash runway 10 months +30
ATM program on file since May 2024 +15
Shelf registration (S-3, Sep 2026) +10
Going-concern doubt in the latest 10-Q +15These factors raise substantial doubt about our ability to continue as a going concern within twelve months following the issuance date of these financial statements.10-Q, Oct 2026
Share count 4,598,968 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full BMRA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BMRA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.